GLP-2 and Tirzepatide: Clearing Up a Common Confusion

Step 1: What GLP-2 actually does in the body

Glucagon-like peptide 2 (GLP-2) is a hormone released by cells in the small intestine, primarily after eating. Its main job is to support the intestinal lining: it promotes gut-wall growth and repair, reduces inflammation in the bowel, and slows how quickly the intestine empties. That makes it medically interesting in conditions involving intestinal damage or short bowel syndrome, but it plays no meaningful role in appetite signalling or blood-sugar control.

GLP-2 and GLP-1 are related (both come from the same precursor protein, proglucagon) but they act on completely different receptors and produce quite different effects. GLP-1 receptors are found in the pancreas, brain, stomach and heart, among other places. Activation there slows gastric emptying, increases feelings of fullness, and helps regulate insulin release. GLP-2 receptors are concentrated in the gut wall itself. The physiological jobs are distinct, which is why researchers developing medicines for obesity and type 2 diabetes focused on GLP-1 (and later GIP), not GLP-2.

Knowing this distinction helps explain why searching for "GLP-2 tirzepatide" turns up so little useful information: the two simply don't overlap. Tirzepatide was engineered to target GLP-1 and GIP, not GLP-2.

Step 2: Where tirzepatide sits, GIP and GLP-1 together

Tirzepatide, sold in the UK under the brand name Mounjaro, is the first medicine licensed here that activates two incretin receptors simultaneously. The GIP and GLP-1 combination is key: GIP (glucose-dependent insulinotropic polypeptide) works alongside GLP-1 to reduce appetite and improve how the body processes glucose, and the two signals appear to reinforce each other in ways that a single-pathway medicine does not replicate.

In the SURMOUNT-1 clinical trial (which involved 2,539 adults with obesity) participants on the highest dose of tirzepatide achieved an average body-weight reduction of around 20–21% over 72 weeks, according to results published in the New England Journal of Medicine. The Mounjaro treatment page covers the full picture on results and the licensed dosing schedule, from the initial 2.5 mg starter pen through to maintenance doses.

Semaglutide (the active ingredient in Wegovy) works on GLP-1 alone. That single-pathway difference between tirzepatide and semaglutide is the most clinically significant comparison in current weight-management medicine. GLP-2 does not enter that comparison at any point.

Step 3: Why the terminology gets muddled online

Several things conspire to create the GLP-2 confusion. First, the naming convention: GLP-1 and GLP-2 sound like a numbered series, which leads some people to assume GLP-2 is simply the next generation. It isn't, the numbering reflects the order in which these peptides were identified from the proglucagon protein, not a hierarchy of potency or modernity.

Second, the phrase "dual GLP" sometimes appears in coverage of tirzepatide, and it is easy to misread as GLP-1 plus GLP-2. What it actually refers to is GLP-1 plus GIP, two separate peptide families, not two versions of the same one. The GLP and tirzepatide overview explains this distinction in plain terms if you want to go deeper on the receptor pharmacology.

Third, GLP-2-based medicines do exist (teduglutide (Revestive) is a GLP-2 analogue licensed for short bowel syndrome in the UK) so the receptor class is real, just unrelated to weight management. No GLP-2 medicine is licensed for weight loss or type 2 diabetes in the UK as of summer 2026, and tirzepatide is not one.

For anyone piecing together what GLP-1 peptide-based treatments mean in practice, or researching whether tirzepatide might suit them, the frequently asked questions page covers eligibility and process in plain language. A question our prescribers hear most weeks is some version of "which receptor does this actually work through?", it's a good question, and the honest answer is that knowing matters when you're choosing between treatments. You can read more about weight-loss treatment options or explore the process for accessing Mounjaro through a regulated UK pharmacy if you're further along in your thinking.

These are prescription-only medicines. A prescriber's assessment (covering your health history, any other medicines you take, and your BMI) is what determines whether tirzepatide is appropriate for you, not a receptor chart. If you'd like that conversation, our prescribers are available. Speak to our prescribers through a free consultation and get a same-day clinical review from a GPhC-registered Independent Prescriber.